RT Journal Article
SR Electronic
T1 A system biology approach identifies candidate drugs to reduce mortality in severely ill COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.14.21262309
DO 10.1101/2021.09.14.21262309
A1 Vinicius M. Fava
A1 Mathieu Bourgey
A1 Pubudu M. Nawarathna
A1 Marianna Orlova
A1 Pauline Cassart
A1 Donald C. Vinh
A1 Matthew Pellan Cheng
A1 Guillaume Bourque
A1 Erwin Schurr
A1 David Langlais
YR 2021
UL http://medrxiv.org/content/early/2021/09/22/2021.09.14.21262309.abstract
AB Despite the availability of highly efficacious vaccines, Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) lacks effective drug treatment which results in a high rate of mortality. To address this therapeutic shortcoming, we applied a system biology approach to the study of patients hospitalized with severe COVID. We show that, at the time of hospital admission, patients who were equivalent on the clinical ordinal scale displayed significant differential monocyte epigenetic and transcriptomic attributes between those who would survive and those who would succumb to COVID-19. We identified mRNA metabolism, RNA splicing, and interferon signaling pathways as key host responses overactivated by patients who would not survive. Those pathways are prime drug targets to reduce mortality of critically ill COVID-19 patients leading us to identify Tacrolimus, Zotatifin, and Nintedanib as three strong candidates for treatment of severely ill patients at the time of hospital admission.Teaser Epigenetics distinguishes COVID-19 survivors already at hospital admission: lessons for drug repurposing.Competing Interest StatementNone of the authors have any relevant conflicts of interest to disclose. Dr. Cheng reports personal fees from GEn1E Lifesciences (as a member of the scientific advisory board), personal fees from nplex biosciences (as a member of the scientific advisory board), outside the submitted work. He is the co-founder of Kanvas Biosciences and owns equity in the company. In addition, Dr. Cheng has a patent for Methods for detecting tissue damage, graft versus host disease, and infections using cell-free DNA profiling pending. Dr. Cheng and Dr. Vinh have a patent for Methods for assessing the severity and progression of SARS-CoV-2 infections using cell-free DNA pending.Clinical TrialNCT04330690Funding StatementThis work was supported by a Canada Institute of Health Research (CIHR) program grant (CEE-151618) for the McGill EMC, which is part of the Canadian Epigenetics, Environment and Health Research Consortium (CEEHRC) Network and a CIHR Project Grant to DL (#168959). DL was also supported by an FRQ-S, Chercheur-Boursier Junior 1 Award and the Canada Foundation for Innovation John R. Evans Leaders Fund. Work in the lab of ES was supported by a Foundation grant from CIHR (FDN-143332) and a Canada Foundation for Innovation John R. Evans Leaders Fund award. GB is supported by a Canada Research Chair Tier 1 award, a FRQ-S, Distinguished Research Scholar award and the Canadian Center for Computational Genomics (C3G) is supported by a Genome Canada Genome Technology Platform grant. MPC was supported by a CIHR grant during the conduct of the study. The work was also supported by an award from the McGill Interdisciplinary Initiative in Infection and Immunity (MI4) to MPC, MB, GB, and ES. This research was enabled in part by support provided by Calcul Quebec and Compute Canada (www.computecanada.ca).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the McGill University Health Centre (MUHC) Research Ethics Board protocol 10-256.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe scRNA-seq datasets for the hospitalized COVID-19 patients are available on the European Genome-Phenome Archive, accession number EGAS00001005468. The CITE-seq datasets from healthy controls were retrieved from 10X Genomics. The other healthy controls scRNA-seq datasets were from previously published studies (L&eacutevy et al, JCI 2021). The ATAC-seq and WGBS datasets are available through the International Human Epigenome Consortium (IHEC) data portal (https://epigenomesportal.ca).